NasdaqGS - Delayed Quote • USD
AbCellera Biologics Inc. (ABCL)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:57 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 7 | 6 |
| Avg. Estimate | -0.17 | -0.16 | -0.65 | -0.7 |
| Low Estimate | -0.25 | -0.25 | -1.01 | -0.99 |
| High Estimate | -0.13 | -0.12 | -0.5 | -0.45 |
| Year Ago EPS | -0.14 | -0.11 | -0.51 | -0.65 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 6 |
| Avg. Estimate | 10.84M | 11.49M | 47.55M | 67.86M |
| Low Estimate | 8.9M | 9.22M | 36.9M | 46.4M |
| High Estimate | 18.29M | 17.36M | 77.46M | 117.86M |
| Year Ago Sales | 12.19M | 10.06M | 38.02M | 47.55M |
| Sales Growth (year/est) | -11.10% | 14.30% | 25.00% | 42.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.14 | -0.13 | -0.13 | -0.13 |
| EPS Actual | -0.14 | -0.11 | -0.1 | -0.17 |
| Difference | 0 | 0.02 | 0.03 | -0.04 |
| Surprise % | 0.00% | 15.40% | 23.10% | -30.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.17 | -0.16 | -0.65 | -0.7 |
| 7 Days Ago | -0.16 | -0.15 | -0.64 | -0.69 |
| 30 Days Ago | -0.16 | -0.15 | -0.64 | -0.69 |
| 60 Days Ago | -0.16 | -0.15 | -0.64 | -0.69 |
| 90 Days Ago | -0.12 | -0.13 | -0.61 | -0.67 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | ABCL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -21.40% | -- | -- | 6.50% |
| Next Qtr. | -45.50% | -- | -- | 12.00% |
| Current Year | -27.50% | -- | -- | 5.30% |
| Next Year | -7.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 10.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | Benchmark: Hold to Buy | 2/22/2024 |
| Maintains | Stifel: Buy to Buy | 2/21/2024 |
| Initiated | Keybanc: Overweight | 12/5/2023 |
| Maintains | Benchmark: Buy to Buy | 8/31/2023 |
| Maintains | Goldman Sachs: Buy to Buy | 8/4/2023 |
| Maintains | Credit Suisse: Outperform | 5/5/2023 |
Related Tickers
NTLA Intellia Therapeutics, Inc.
20.76
+3.70%
DNA Ginkgo Bioworks Holdings, Inc.
0.8601
+10.60%
BEAM Beam Therapeutics Inc.
21.38
-1.02%
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
ADPT Adaptive Biotechnologies Corporation
2.6000
-0.38%
CRBU Caribou Biosciences, Inc.
3.7100
-1.33%
EDIT Editas Medicine, Inc.
5.32
+1.92%
CRSP CRISPR Therapeutics AG
53.91
+0.34%
EXAI Exscientia plc
4.0300
+1.00%
PRME Prime Medicine, Inc.
4.4250
+2.91%